Agilent Technologies Inc. (NYSE: A) today announced the company will participate in the Wells Fargo 2020 Virtual Healthcare Conference on Wednesday, Sept. 9. A webcast of the event will be available for the investment community. The details:
What: Wells Fargo 2020 Virtual Healthcare Conference
When: Wednesday, Sept. 9 at 10:40 a.m. (EDT)
Who: Bob McMahon, Agilent chief financial officer
When they become available, links to join the webcast may be found in the "News & Events – Events” section of the Investor Relations portion of the Agilent website.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005803/en/
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that preclinical data related to camidanlumab tesirine (Cami, formerly ADCT-301) has been published in the Journal for ImmunoTherapy of Cancer, the online journal of the Society for Immunotherapy of Cancer, in a paper titled, "CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.”
The study evaluated the antitumor activity of a pyrrolobenzodiazepine (PBD) dimer-based, CD25-targeted ADC, either alone or in combination with a checkpoint inhibitor, in CD25-negative syngeneic colon cancer models that exhibit tumor infiltration of CD25-expressing regulatory T cells (Tregs). Data demonstrated that single low doses of the CD25-targeted ADC resulted in potent and durable antitumor activity against established CD25-negative solid tumors with infiltrating Tregs, both as a monotherapy and in combination with an anti-PD1 checkpoint inhibitor.
Patrick van Berkel, Ph.D., Senior Vice President of Research and Development at ADC Therapeutics, said, "CD25 is expressed on Tregs that infiltrate the local tumor environment. We were pleased to see that our CD25-targeted ADC depleted CD25-expressing Tregs and not only showed strong anti-tumor activity as a monotherapy in preclinical models, but it also enhanced the activity of anti-PD1 treatment in these models. This study provides proof of concept for a new application of ADCs as immunotherapeutic agents and supports the continued evaluation of Cami in our ongoing Phase 1b clinical trial in patients with selected advanced solid tumors. We look forward to advancing the exploration of Cami as a novel immune-oncology approach for the treatment of solid tumors.”
For information about the company’s Phase 1b clinical trial of Cami in solid tumors, visit www.clinicaltrials.gov (identifier NCT03621982).
About Camidanlumab Tesirine (Cami)
Camidanlumab tesirine (Cami, formerly ADCT-301) is an antibody drug conjugate (ADC) comprised of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine (PBD) dimer payload, tesirine. Once bound to a CD25-expressing cell, ADCT-301 is internalized into the cell where enzymes release the PBD-based warhead killing the cell. This applies to CD25-expressing tumor cells, and also to CD25-expressing Tregs. The intra-tumoral release of its PBD warhead may also cause bystander killing of neighboring tumor cells and PBDs have also been shown to induce immunogenic cell death. All these properties of Cami may enhance immune-mediated anti-tumor activity. Cami is being evaluated in a pivotal Phase 2 clinical trial in patients with relapsed or refractory Hodgkin lymphoma (HL), as well as in a Phase 1a/1b clinical trial in patients with relapsed or refractory HL and non-Hodgkin lymphoma and a Phase 1b clinical trial in solid tumors.
About ADC Therapeutics
ADC Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which ADC Therapeutics has proprietary rights for its targets. Strategic target selection for PBD-based ADCs and substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipeline of therapies for the treatment of hematological and solid tumor cancers. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase 2 clinical trials, in the USA and Europe, and numerous preclinical ADCs in development.
Loncastuximab tesirine (Lonca, formerly ADCT-402), the Company’s lead product candidate, has been evaluated in a 145-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that showed a 48.3% overall response rate (ORR), which exceeded the target primary endpoint. Camidanlumab tesirine (Cami, formerly ADCT-301), the Company’s second lead product candidate, is being evaluated in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma (HL) after having shown an 86.5% ORR in HL patients in a Phase 1 clinical trial. The Company is also evaluating Cami as a novel immuno-oncology approach for the treatment of various advanced solid tumors.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005550/en/
NEO price is enjoying a great month as it gained to log 2-year highs at $25.90
Neo Foundation is planning to use its roughly 42.24 million NEO holdings to mint FLM tokens
A break of $21.00 activated the double chart pattern as bulls target a move to $36.00
Neo (NEO) price is enjoying a great month as it gained to log 2-year highs at $25.90. After breaking the $21.00 handle, the buyers activated a double bottom chart pattern which may push the price action to $36.00 in the coming months.
Fundamental analysis: Neo to acquire FLM tokens
The Foundation said it doesn’t plan to use the majority of its NEO holdings to amass FLM tokens in the course of the Flamingo Finance Mint Rush. The foundation wants to accumulate a “minority share” during the Mint Rush, scheduled to begin on September 25th.
Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today.
Concerns emerged recently in the Neo community that the foundation is planning to use its roughly 42.24 million NEO holdings to mint FLM tokens. The community expressed its concerns about an unjust FLM token distribution to NEO token holders, or that the foundation may capitalize on coffers created to support the development of the Neo ecosystem.
Yuan Gao, head of marketing at NGD, said that Neo Foundation plans to use only a percentage of its holdings to take part in the Mint Rush, rather than use the majority.
“The Neo Foundation won’t stake all of its NEO into [Flamingo]; there is too much. It doesn’t make sense for the Foundation to mint most of the FLM because it’s a [decentralized finance] project, and won’t work that way if one party takes the majority stake of the token. So, the Neo Foundation is going to have a minority share.”
He said the foundation wants to acquire FLM for two main reasons. First, the foundation wants to offer liquidity to Flamingo’s new Swap module, an on-chain exchange. In order for the Swap module to operate, it needs an accessible pool that includes NEO, GAS, NEP-5, and other supported tokens to trade.
The second reason is that NF plans to take part in future voting and management processes, in which FLM tokens have an essential role. Neo Foundation and Neo Global Development will govern the Flamingo project directly in its early stages.
However, the plan is to pass the management responsibility to the community, which will decide on the further direction of Flamingo through a decentralized autonomous organization (DAO) administration model.
Technical analysis: Double bottom chart pattern
NEO/USD price is currently in the correction mode after gaining over 16% last week to trade above the near-term resistance at $21.00. This is also a neckline of the double bottom chart pattern, which has a measured target at $36.00. The pattern is now activated and buyers will look to push the price action towards this milestone.
NEO/USD price daily chart (TradingView)
Looking in the short-term, the price action has now returned lower to retest the broken resistance, which now acts as support. Hence, this is an opportunity for the new NEO buyers to get on the long side and place their stops below the support line.
NEO/USD has activated the double-bottom chart pattern at $21.00, and the bulls will now aim to complete the formation at $36.00. In the meantime, the Neo Foundation said it will use only a minor percentage of its NEO tokens to accumulate FLM tokens during the Flamingo Finance Mint Rush.